Prolonging the survival period of cancer patients is a glimmer of hope in life. With continuous breakthroughs in treatment methods and drugs, this dream can come true!
Immune cell therapy has become the fourth type of cancer treatment, but it is expensive for patients and its effectiveness is challenged, and some even have to go abroad to get it.
Now, domestic biomedical industry and a Japanese company that has accumulated experience in treating 22 types of cancer and more than 100,000 cancer patients have technologically cooperated with the "dendritic cell cancer vaccine" therapy. In the future, Taiwanese cancer patients will be able to use this therapy to achieve clinical efficacy.
The function of cancer cells is to inhibit the growth of tumors or the spread of cancer cells, convert "cold tumors into hot tumors", and exert the function of poisoning and killing cancer cells!
Xinpin Biomedical announced that it has cooperated with the Japanese listed company Tella Group to license two important patented technologies for immune cell preparations, including "DC (dendritic cell) cancer vaccine" and "Super NK (natural killer) cells".
Domestic biomedical companies have introduced and authorized two immune cell preparation patented technologies from Japan. After the Ministry of Health and Welfare relaxed the regulation of immune cells for clinical treatment of multiple cancers, Xinpin Biomedical announced that it has cooperated with the Japanese listed company Tella Group to authorize "DC (
Two important patented technologies for immune cell preparations, including dendritic cells (cancer vaccines) and "super NK (natural killer) cells".
Clinicians and cancer patients can expect to benefit from Japan’s immune cell culture technology and experience accumulated over the past 15 years in Taiwan.
Pan Junyou, chairman of Xinpin Biomedical, pointed out that the "DC (dendritic cell) cancer vaccine" therapy introduced into the country by Xinpin Biomedical this time was developed by the University of Tokyo.
It has been used by more than 11,000 cancer patients in Japan for 22 types of cancer, including pancreatic cancer, which has relatively unsatisfactory results from conventional anti-cancer treatments, colorectal cancer, which has the largest number of new cases in the country, and lung cancer, which has the highest number of deaths.
.
What is a "dendritic cell cancer vaccine?" Professor Naohide Yamashita, emeritus professor at the University of Tokyo, said that dendritic cells (DC) are a type of immune cell that exists in the human body and are mainly derived from hematopoietic stem cells in human bone marrow.
Dendritic cells are like the commanders of the body's defense system and have the ability to phagocytose and present antigens.
When dendritic cells recognize foreign pathogens or cancer cells, they will begin phagocytosis and break down these cancer cells into small fragments. They will then present the antigens of the cancer cells on the surface of the dendritic cells to train T cells to recognize these cancer cells.
, in order to achieve the purpose of using immune cells (T cells) to accurately and effectively attack cancer cells.
Tella President Yuichiro Yazaki pointed out that the dendritic cell vaccine first obtains mononuclear spheres from the patient's blood, culture them into dendritic cells in vitro, and then adds protein fragments with the characteristics of the target cancer, which are the so-called cancer cell antigens, to make the dendritic cells more effective.
The cells remember the characteristics of the cancer cells and are then injected into the patient's body to induce an immune response against the cancer cells.
Dendritic cell vaccines can enhance the body's immune response to cancer cells and are often used in conjunction with existing treatments such as surgery, radiotherapy and chemotherapy, and targeted therapies to help the body eliminate remaining cancer cells in the body.
Professor Lai Jiming, Director of the Cancer Center of Wanfang Hospital, pointed out that the future of immune cell therapy can be foreseen and patients are full of expectations.
Why does "dendritic cell vaccine therapy" help turn "cold tumors into hot and swollen tumors?" The so-called "cold tumors" and "hot tumors" actually refer to tumors that are immunogenic (hot tumors) and tumors that are not immunogenic.
Tumors (cold tumors), cold tumors are those with no or very few immune cells in the tumor tissue. In the past, the efficacy of immunotherapy alone for such patients was poor.
"Dendritic cell vaccine therapy" can help increase immune cells and activate immune checkpoint inhibitors, reducing the chance of tumor cells engaging in a "death grip" with immune cells, thereby killing cancer cells.
Checkpoint inhibitors relieve the brake effect of tumors on immune cells, and then these immune cells can easily blow the burning flames to the base occupied by cancer cells, thus having a therapeutic effect on "hot tumors".
"Dendritic cell vaccine therapy" that uses autologous immune cells to attack cancer cells will be submitted for application as soon as possible and is expected to be available for clinical use in Taiwan by the end of the year at the earliest.
Professor Lai Jiming, CEO of the Taiwan Cancer Foundation and Director of the Cancer Center of Wanfang Hospital, pointed out that the NK cells provided by immune cell therapy are like various armed forces of the Communist Party, forming a human sea tactic to attack cancer cells.
If combined with immune check inhibitors, immune cells that have been suppressed and released will again receive help from immune cells, which can greatly enhance the effect of immunotherapy.
After the special control measures are implemented, as long as orthodox medical institutions and dedicated doctors develop treatment plans, submit applications for clinical application, and have cell products manufactured by GTP laboratories with qualified culture and amplification equipment, there will be
By applying and treating cancer patients, we can foresee the future of immune cell therapy and make patients full of expectations.